Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.30 |
| ▸ | TUBB | P07437 | 1/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.30 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.30 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.30 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.30 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.30 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.30 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.30 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29853016 | 0.72 | IDO1 (0.42) | IDO1MEN1KMT2AHTR2AHTR2C | |
| SCHEMBL560920 | 0.72 | IDO1 (0.42) | IDO1MEN1KMT2AHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL23218712 | 0.72 | IDO1 (0.42) | IDO1MEN1KMT2AHTR2AHTR2C | |
| SCHEMBL31142935 | 0.72 | IDO1 (0.42) | IDO1MEN1KMT2AHTR2AHTR2C | |
| SCHEMBL30525679 | 0.70 | MEN1 (0.41) | IDO1MEN1KMT2AHTR2AHTR2C | |
| SCHEMBL23536830 | 0.70 | GABRA1 (0.52) | IDO1MEN1KMT2AHTR2AHTR2C | |
| SCHEMBL1364220 | 0.70 | MEN1 (0.41) | IDO1MEN1KMT2AHTR2AHTR2C | |
| SCHEMBL7663813 | 0.69 | MEN1 (0.43) | IDO1MEN1KMT2AHTR2AHTR2C | |
| SCHEMBL560783 | 0.69 | MEN1 (0.43) | IDO1MEN1KMT2AHTR2AHTR2C | |
| SCHEMBL29246782 | 0.69 | MEN1 (0.40) | IDO1MEN1KMT2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20180344692-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-12-06 | — | — | US | disclosed |
| EP-2303264-B1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| EP-2932968-B1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9849113-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9623006-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2932968-A1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8063231-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2377534-A1 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2303264-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | Allergan, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009152053-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATES | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152052-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | IDO1 1866/4885MEN1 3787/4885KMT2A 3926/4885 |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | IDO1 1881/4885MEN1 3477/4885KMT2A 3972/4885 |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | IDO1 1866/4885MEN1 3787/4885KMT2A 3926/4885 |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | IDO1 1866/4885MEN1 3787/4885KMT2A 3926/4885 |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | IDO1 1881/4885MEN1 3477/4885KMT2A 3972/4885 |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | IDO1 1881/4885MEN1 3477/4885KMT2A 3972/4885 |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | IDO1 1881/4885MEN1 3477/4885KMT2A 3972/4885 |
| US-20180344692-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | IDO1 1881/4885MEN1 3477/4885KMT2A 3972/4885 |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | IDO1 1881/4885MEN1 3477/4885KMT2A 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.